Schering Aktiengesellschaft

Genentech, Inc.

Bayer Schering Pharma Ag

Bayer Intellectual Property Gmbh

Celtaxsys, Inc.

Bayer Healthcare LLC

Genetech, Inc.

Celltaxis, LLC

Celltaxsis, LLC

Estrellita Pharmaceuticals, LLC

Schering Altiengesellschaft

Bayer Pharma Aktiengesellschaft

David Richard Light

Thomas A Kirkland

William J Guilford

Arwed Cleve

Monica J Kochanny

Bin Ye

Guo Ping Wei

John V Parkinson

Seock-Kyu Khim

Emmanuel Claret

Amy Liang

Greg Brown

David D Davey

Damian O Arnaiz

William H Rastetter

Michael John Morser

Kirk McLean

William H Andrews

Jeffrey Homer Clarke

Robert Michael Wydro

Patricia Ann Young

David Aaron Estell

Renate Parry

Douglas W Schneider

Mariko Nagashima

David Vogel

Noboru Satozawa

Tara Renee Heitner Hansen

Charles B Glaser

Mark S Dennis

Stephen P Anderson

Robert A Lazarus

Stefan Steidl

Cara B Marks

Antje Kahnert

Ulrike Schubert

Doug Schneider

Jeffrey V Miller

Marian Seto

David Davey

Bing Liu

Zhuozhi Wang

Kirk Mclean

Wang Zhuozhi

Liu Bing

Douglas Schneider

Tara Heitner

This invention is directed to compounds of formula (I): where r, q, R, R, R, R, R, R, R, R, R, R, R, R, and Rare described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene Ahydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.

Diamine derivatives as inhibitors of leukotriene Ahydrolase

Diamine derivatives as inhibitors of leukotriene A4 hydrolase

This invention relates to monospecific and multispecific antibodies that may be utilized for the diagnosis and treatment of various diseases. In addition, these antibodies may be modified by protease cleavage. Protease control or regulation may be provided by a protease site located in, for example, a linker. These protease-regulated antibodies may also be utilized for the diagnosis and treatment of various diseases.

Monospecific and multispecific antibodies and method of use

The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 4O.kDa mesothelin polypeptide, which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of mesothelin in the progression of disorders associated with cancer. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.

Anti-mesothelin antibodies and uses thereof

Dimeric molecular complexes useful for diagnostics and therapeutics.

Dimeric molecular complexes

This invention relates to novel antibodies that bind with greater affinity to the factor VIIa/tissue factor (FVIIa/TF) complex than to tissue factor (TF) alone, do not compete for binding to TF with FVII and FX, an inhibit FX activation. The antibodies bind at the site of injury and prevent the initiation of thrombosis. The antibodies can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.

Polynucleotides encoding anticoagulant antibodies

[object Object]

Tissue factor targeted antibodies as anticoagulants

This invention relates to novel fusion proteins which are comprised of a targeting protein that binds tissue factor (TF), which is operably linked to the thrombomodulin (TM) EGF456 domain alone or in combination with at least one other TM domain selected from the group consisting of the N-terminal hydrophobic region domain, the EGF123 domain, the interdomain loop between EGF3 and EGF4, and the O-glycosylated Ser/Thr-rich domain, or analogs, fragments, derivatives or variants thereof. The fusion protein binds at the site of injury and prevents the initiation of thrombosis. The fusion protein can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.

Tissue factor targeted thrombomodulin fusion proteins as anticoagulants

The present invention relates to the design, production and use of analogs of thrombomodulin (TM) that have the ability to enhance the thrombin-mediated activation of protein C but which have a significantly reduced ability to promote activation of thrombin-activatable fibrinolysis inhibitor (TAFI). These analogs are useful in, for example, antithrombotic therapy.

Thrombomodulin analogs for pharmaceutical use

The present invention relates to the single-chain thrombomodulin ('TM') and analogs thereof that are not susceptible to cleavage by proteases and retain the biological activity of thrombomodulin, as well as methods of use in, for example, antithrombotic therapy. Novel proteins, nucleic acid gene sequences, pharmaceuticals and methods of inhibiting thrombotic activity are disclosed.

Protease-resistant thrombomodulin analogs

Growing community of inventors

San Mateo, CA, United States of America

David Richard Light